BH3 mimetics are a class of anticancer agents that hold the promise to trigger the central apoptotic machinery to set cancer cells on the road to ruin. Now, a new agent that selectively targets BCL-2, ABT-199, has been developed, with exciting preclinical and clinical results (pages 202–208).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Souers, A.J. et al. Nat. Med. 19, 202–208 (2013).
Green, D.R. Means to an End: Apoptosis and Other Cell Death Mechanisms (CSHL Press, 2011).
Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J. & Green, D.R. Mol. Cell 37, 299–310 (2010).
Vo, T.T. et al. Cell 151, 344–355 (2012).
Oltersdorf, T. et al. Nature 435, 677–681 (2005).
Tse, C. et al. Cancer Res. 68, 3421–3428 (2008).
van Delft, M.F. et al. Cancer Cell 10, 389–399 (2006).
Mason, K.D. et al. Cell 128, 1173–1186 (2007).
Beroukhim, R. et al. Nature 463, 899–905 (2010).
Gavathiotis, E., Reyna, D.E., Bellairs, J.A., Leshchiner, E.S. & Walensky, L.D. Nat. Chem. Biol. 8, 639–645 (2012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Green, D., Walczak, H. Apoptosis therapy: driving cancers down the road to ruin. Nat Med 19, 131–133 (2013). https://doi.org/10.1038/nm.3076
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3076